Pain Therapeutics receives complete response letter

The Food and Drug Administration issued a complete response letter to Pain Therapeutics Inc. (Nasdaq: PTIE) saying that its New Drug Application for Remoxy ER could not be approved in its current form. Shares of the biopharmaceutical plummeted $1.40 to close at $1.33.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.